Highly Experienced Scientist & Research Director
A highly experienced scientist and research director with more than 20 years of progressively increasing responsibilities in preclinical and clinical research programs, development, management, recruitment and training of research staff, preparation of proposals and data analyses with presentations to professional societies and foundations.
Expertise includes outstanding organizational, project management, marketing, regulatory compliance, medical and community relations and negotiation skills.
City of Hope National Medical Center, Duarte, California 2003-2004
Assistant Director, Clinical Research Management
Headed the Clinical Research Management section in the Division of Information Sciences, primarily focusing on process management in support of more than 400 cancer-related clinical trials annually. Oversaw and supervised Clinical Trial Administrators (CTAs) and 40 Clinical Research Associates (CRAs), Wrote and maintained standard operating procedures (SOPs) for clinical trials. Participated in case report form development, assisted in workload assessment and alignment, coordinated recruitment and augmented retention.
- Managed the in-house pharmaceutical company, university and co-op group clinical trials.
- Established and implemented new procedures for interviewing, hiring, training and motivating new CRAs.
- Interfaced, collaborated and served as a liaison with 30 physicians in clinical trial implementation.
- Managed resources, budgets and workloads, ensuring that clinical trials were complete, on time and within regulatory standards.
BIS/IMPATH Inc., Los Angeles, California 1997-2002
Director, Research & Development
Identified, facilitated and cultivated collaborative relationships with major pharmaceutical companies, hospitals, research centers, government agencies, physicians and research scientists; generated 30 clinical research and oncology trial study contracts with Bayer, National Health Institute, Amgen, John Hopkins Medical Center, M.D. Anderson, Pfizer, City of Hope and many others. Directed and managed 20 clinical research professionals.
- Supported field-based marketing representatives as an oncology, scientific and medical liaison, providing scientific and medical expertise, educational support and marketing strategies.
- Managed pre-clinical and clinical trial projects for new oncology product development and comprehensive tumor analysis services. Acted as Principal Study Director, designing studies, developing proposals and protocol and approving final reports for functional properties and validity of data.
- Assured the highest quality of clinical work, following FDA regulations, internal SOPs and auditing processes.
- Prepared the budget for pre-clinical and clinical study programs.
- Coordinated and monitored publication/presentation strategies, including the review of scientific journals and publications. Prepared data and submitted scientific and clinical abstracts, manuscripts and patent applications.
- Provided leadership to clinical research and clinical staff for appropriate training.
- Attended regional and national trade and scientific conferences, communicating with clients to ascertain their needs, resulting in new relationships.
- Increased revenue by $80 million.
- Educated physicians, oncology specialists, customers, prospective clients and sales professionals on interpretation of clinical trial results.
Cedars-Sinai Medical Center, Hematology/Oncology, Los Angeles, California 1992-1997
Research Scientist III
Directed a team of scientists in the study of molecular and cellular aspects of programmed cell death (apoptosis) in cancer, utilizing flow cytometry and immunoassays.
- Developed a Scid/Mouse model to study the induction of apoptosis in vivo in leukemia.
- Developed a bone marrow stromal cell system that grew stem cells and progenitors and leukemia cells.
Beilinson Medical Center, Petah-Tikva, Israel 1983-1990
Director, Research & Flow Cyometry Laboratory, Department of Pediatrics, Hematology-Oncology
Established and supervised a new bone marrow transplantation laboratory that included purging of leukemia and neuroblastoma with monoclonal antibodies.
- Mentored six technicians, MD fellows and post-doctoral students.
- Directed the laboratory for bone marrow transplantation for cancer patients. Established and directed a new flow cytometry facility that phenotyped leukemia/lymphoma, sorted tumor cells and provided accurate and faster diagnostic tools for cancer detection.
- Directed clinical projects. Results included the identification of a new entity of stem cell leukemia with the potential to differentiate along the lymphoid or myeloid pathways and stem cell analysis of cancer patients and normal individuals.
- Actively participated in workshops on human leukocyte antigens to determine the relationships between structure and function of monoclonal antibodies. Tested prospective antibodies for workshops, which led to an international nomenclature to classify the human leukocyte differentiation antigens, i.e., cluster of differentiation (CD).
Studied various differentiation stages of human B and T cells at the Dana Farber Cancer Institute, Harvard Medical School. This laboratory was the leader in developing monoclonal antibodies to human differentiation antigens using novel hybridoma and flow cytometry technologies. Previously, as Senior Scientist at the Weizmann Institute of Science, Rehovot, Israel, studied the ontogeny and characteristics of T cells and natural suppressors in fetal liver, decline of immunocompetent stem cells during aging and prevention of graft vs. host disease (GVHD). Mentored doctoral candidates, MD fellows and technicians.
University of California, Los Angeles, Anderson School of Business, Los Angeles, California
Executive Management Program, Certificate
University of Wisconsin, Madison, Wisconsin
Post-Doctoral Fellow, Immunobiology
Doctor of Philosophy, Biology (Immunology) and Science Education
Thesis: Immunocompetent Cells Developing in the Fetal Liver
Master of Science, Biology and Science Education
Bar Ilan University, Ramat Gan, Israel
Degree in Teaching, High School Level Science
Conduct seminars and workshops - subjects include cancer prevention, maximizing natural immune defenses, adding meaningful years to your life, what every woman should about breast cancer, new breakthroughs in defeating cancer and what every man should know about prostate cancer.
American Association for the Advancement of Science
American Society of Hematology
American Society of Clinical Oncology
American Association of Immunologists
Adjunct Associate Professor, UCLA School of Medicine, Los Angeles
Anderson Alumni, UCLA Anderson School of Business, Los Angeles
Articles in Peer-Reviewed Journals:
Joyce RM, Regan M, Ottaway J, Umiel, T, Tetreault JC, Levine J, McDermott D, Hurley D, Giallombardo N, Smith T, Lamontagne D, Uhl L, Avigan D. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkins's lymphoma prior to and after high-dose chemotherapy and autolagous stem cell transplantation (HDC-ASCT). Ann Oncol. 4 Suppl 1:i21-27, 2003.
Wirtchafter A, Benninger MS, Moss TJ, Umiel T, Blazkoff K, Worsham MJ. Micrometastatic tumor detection in patients with head and neck cancer: a preliminary report. Arch Otolarygol Head Neck Surg. 128: 40-43, 2002.
Burgess J, Mills B, Griffith M, Mansour, V, Weaver CH, Schwartzberg LS, Snyder EL, Drause DS, Yanovich S, Prilutskaya M, Umiel T, Moss TJ. Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34(+) cells. Cytotherapy. 3:285-294, 2001.
Joyce RM, Kraser CN, Tetrealt JC, Giallombardo N, McDemott D. Levine J, Umiel T, Regan M, Hurley D, Uhl L, Avigan D. Rituimab and ifofamid, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non- Hodgkin's lymphoma prior to high-dose chetherapy with autologoushematopoietic transplant. Eur J. Hematol Suppl. 64: 56-62, 2001.
Umiel T, Priluskaya M, Nguyen NH, Moss TJ, Schaffer A, Burgess J, Griffith M, and Mills B. Breast tumor contamination of peripheral blood stem cell harvest. I Increased sensitivity of detection using immunomagnetic enrichment. J Hematother Stem Cell Res. 9:895-904, 2000.
Elstner E, Linker-Israeli M, Le J, Umiel T, Micl P, Said JW, Binderup L, Reed JC, Keffler HP. Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi-vitamin D3 analogs and 9-cis retinoic acid. J Clin Inves 99: 349-360, 1997.
Grillier I, Umiel T, Elstner E, Collins SJ, Keoffler HP. Alteration of differentiation, clinal proliferation, cell cycle progression and bcl-2 expression in RAR alpha-altered subline of HL-60. Leukemia 11: 393-400, 1997
Moss TJ, Cooper B, Lazarus HM, MEagher R, Rosenfeld C, Pecora A, Herzig RM, Umiel T, et al. Immunocytochemical analysis of bone marrow from patients with stage IV breast cancer undergoing autologous transplant therapy. Hematopathology, 1997.
Elnster E, Linker-Israeli M, Umiel T, Le J, Said J, Shintaku PI, Krajewsk S, Reed JC, Binderup L, and Koeffler HP. Combination of a potent 20-epi-vitamin D3 analog (KH 1060) with 9-cis-retinoic-acid inhibits irreversibly clonal growth, decreases bcl-2 expression and induces apoptosis in HL-60 leukemia cells. Cancer Res 56:3570-3576, 1996.
Elstner E, Linker-Israeli M, Said J, Umiel T, De Vos S, Shintaku P, Heber D, Binderap L, Uskovic M, and Koeffler HP. 20-epi-Vitamin D3 Analoges: A novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 55:2822-2830, 1995.
Umiel T, Pattengale P and Weinberg K. Recombination activating gene-1 (RAG-1) expression in all differentiation stages of B-lineage precursors acute lymphoblastic leukemia. Leukemia 7:435-440, 1993.
Umiel T, Rettenmieir CW, Siegel S, Ota S, Shimada H, Tan TW and Pattengale PK. Establishment and characterization of a human mix-lineage T lymphoid/myeloid cell line (USP-91) from a patient with non-Hodgkin's lymphoma. Blood 82:1829-1837, 1993.
Tamary H, Kaplinsky C, Shvartmayer S, Umiel T, Pecht M, Levin S, Zaizov R. Transient erythroblastopenia of childhood. Evidence for cell-mediated suppression of erythropoiesis. Am J Hematol Oncol 15: 386-391, 1993.
Hendriks D, DeMeester I, Umiel T, Vanhoof G, van Sande M, Scharpe and Yaron A. Aminopeptidase P and dipeptidyl peptidase IV activity in human leukocytes and in stimulated lymphocytes. Clinica Chimica Acta 196 (1991) pgs 87-96.
Umiel T, Monselise J, Klein T, Singer R, Fenig E, Rakovsky E, Lurie H, Adler A. Recombinant interleukin-2 (rIL-2) activated intra-cavitary lymphocytes: phenotypic characteristics and effector function. J Biol Res Mod 8:409-421, 1989.
Stark B, Umiel T, Mammon Z, Rechavi G, Nir E, Cohen IJ, Vogel R, Kaplinsky C, Potaznik D, Katzir N, Ramot B, Zaizov R. Biologic and cytogenetic characteristics of leukemia of infants. Cancer 63:117-125, 1989.
Gluck U, Zipori D, Zaizov R, Luria D, Umiel T. Long-term proliferation of leukemia cells induced by mouse stroma. Exp Hematol 17:398-405, 1989.
Rechavi C, Brok-Simoni F, Katzir N, Mandel M, Umiel T, Stark B, Zaizov R, Ben-Bassat I, Ramot B. More than two immunoglobulin heavy chain J region genes in the majority of infant leukemia. Leukemia 2:347-349, 1988.
Umiel T, Luria D, Stark B, Cohen IJ, Kodman Y, Grunspan A, Dvir A, Yaniv I, Goshen Y, Kaplinsky H, Zaizov R. Heterogeneity of childhood acute lymphoblastic leukemia: monoclonal antibodies phenotyping and induction of differentiation in vitro. Leukemia 88 S-96S, 1988.
Umiel T, Nadler LM, Cohen IJ, Levine H, Stark B, Mammon Z, Djaldetti M, Rechavi G, Simoni F, Katzir N, Ramot B, Zaizov R. Undifferentiated leukemia of infancy with t(11:17) chromosomal rearrangement, coexpressing myeloid and B cell restricted antigens. Cancer 59:1143-1149, 1987.
Goshen Y, Kaplinsky C, Umiel T, Pecht M, Zaizov R. Autoimmune thrombocytopenic purpura preceding Hodgkin's lymphoma in a child. Evidence of impaired NK activity. Restored in vitro by IL2. Harefuah (printed in Hebrew), CXIII 9:209-215, 1987.
Stark B, Cohen IJ, Pecht M, Umiel T, Apte RN, Friedman E, Levine S, Vogel R, Schlesinger M, Zaizov R. Immunological dysregulation in a patient with familial hemophagocytic lymphohistiocytosis. Cancer 60:2629-2636, 1987.
Orgad S, Malone G, Zaizov R, Marinowitz U, McLane MF, Umiel T, Cohen IJ, Vogel R, Cohen-Avishai, Ramot B, Gazit E, Essex M. Antibody to HIV in Israeli hemophiliacs: relationship between serological profile and disease development. AIDS Research and Human Retroviruses 3:323-332, 1987.
Umiel T, Friedman S, Zaizov R, Cohen IJ, Gozes Y, Epstein N, Kobiler D, Zipori D. Long-term culture of infant leukemia cells: dependent upon stroma cells from bone-marrow and bilineage differentiation. Leuk Res 10:1007-1012, 1986.
Umiel T, Nadler LM, Levine H, Stark B, Cohen IJ, Zaizov R. Acute leukemia with mixed lymphoid and myeloid phenotype. Brit J Hematol 62:196-197, 1986.
Stark B, Umiel T, Mammon Z, Galili N, Djaldetti M, Cohen IJ, Vogel R, Zaizov R. Leukemia of early infancy: early B cell lineage associated with t(4:11). Cancer 58:1265-1272, 1986.
Zaizov R, Cohen IJ, Luria D, Trainin N, Umiel T. In vitro restoration by interleukin 2 (IL-2), receptor expression and T-cell proliferation in hemophilia. J Biol Res Modi 5:339-350, 1986.
Barak Y, Karov Y, Barash A, Umiel T, Rosenberg M, Netzer L, Lancet M, Levine S. Lymphoid cells and granulocytes progenitors in early human fetal liver. Immunological parameters in in-vitro cellular interaction. Isr J Med Sci 21:12-18, 1985.
Umiel T, Pecht M, Trainin N. THF, a thymic hormone promotes interleukin-2 production in intact and thymus deprived mice. Biol Resp Modif 3:423-434, 1985.
Umiel T, Friedman E, Luria D, Cohen IJ, Netzer L, Pecht M, Trainin N, Zaizov R. Impaired immune regulation in children and adolescents with hemophilia and thalassemia in Israel. Amer J Ped Hematol Oncol 6:371-378, 1985.
Mukamel E, Umiel T, Shohat B, Servadio C, Trainin N. A quantitative in vivo test for assessment of human lymphocyte immunocompetence. Immunobiology 169:21-29, 1985.
Rosenthal P, Rimm IJ, Umiel T, Griffin JD, Osathanondh R, Schlossman SF, Nadler LM. Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies. J Immunol 131:232-237, 1983.
Sidi Y, Umiel T, Trainin N, Pinkhas J, Sperling O. Differences in the activity of adenosine deaminase and of purine nucleoside phosphorylase and in sensitivity to deoxy purine nucleoside between subpopulations of mouse thymocytes. Thymus 4:147-153, 1982.
Rabinovich H, Umiel T, Globerson A. T cell progenitors in the mouse fetal liver. Transplantation 35:40-48, 1982.
Umiel T, Daley JF, Bhan AK, Levey RH, Schlossman SF, Reinherz EL. Acquisition of immune competence by a subset of human cortical thymoscytes expressing mature T cell antigens. J Immunol 29:1054-1060, 1982.
Globerson A, Abel L, and Umiel T. Immune reactivity during aging. III. Removal of peanut-agglutinin binding cells from aging mouse spleen cells leads to increased reactivity in mitogens. Mechanism of Aging and Development 16:275-279, 1981.
Rabinovich H, Umiel T, Reisner Y, Sharon N, Globerson A. Characterization of embryonic liver suppressor cells by PNA. Cell Immunol 43:347-355, 1979.
Umiel T, Linker-Israeli M, Itzchaki M, Trainin N, Reisner Y, Sharon N. Inhibition or acceleration of tumor growth by subpopulations of thymus cells separable by a peanut lectin. Cell Immunol 37:134-141, 1978.
Globerson A, Umiel T. Ontogeny of suppressor cells. II. Ontogeny of the MLC and GVH response. Transplantation 26:438-442, 1978.
Gozes Y, Umiel T, Meshorer A, Trainin N. Syngeneic GVH induced in popliteal lymph nodes by spleen cells of old C57BL mice. J Immunol 121:2199-2204, 1978.
Umiel T, Globerson A, Trainin N. Development of immunosuppressor cells: exertion of specific suppression by neonatal liver cells. Transplantation 24:282-289, 1977.
Umiel T, Trainin N. The role of the thymus in the establishment of suppresser cells in liver chimeras. Cell Immunol 23:232-239, 1976.
Umiel T. Specific inhibition of graft-versus-host reaction in fetal or neonatal liver chimeras. Transplantation 19:485-494, 1975.
Umiel T, Trainin N. Increased reactivity of responding cells in the mixed lymphocyte reaction by a thymic humoral factor. Eur J Immunol 5:85-88, 1975.
Globerson A, Zinkernagel RM, Umiel T. Immunosuppression by embryonic liver cells. Transplantation 20:480-484, 1975.
Trainin N, Zipori D, Umiel T. Recent studies on the role of the thymus in early stages of lymphopoiesis and immune differentiation. Boll 1st Sieroter. Milanese 54:211-218, 1975.
Umiel T, Globerson A. Analysis of lymphoid cell types developing in mouse fetal liver. Differentiation 2:169-178, 1974.
Umiel T and Trainin N. Immunological enhancement of tumor growth by syngeneic thymus derived lymphocytes. Transplantation 18:244-250, 1974.
Umiel T. Requirements for development of immunocompetence of liver cells: the graft-versus-host response. Differentiation 1:295-300, 1973.
Gozes Y, Umiel T, Trainin N. Selective decline in differentiation capacity of immunohemopoietic stem cells with aging. Mechanism of Aging and Development 18:251-257, 1972.
Umiel T, Globerson A, Auerbach R. Role of the thymus in the development of immunocompetence of embryonic liver cells in vitro. Proc Soc Exp Biol Med 129:598-600, 1968.
Elsther E, De Vos S, Pakkala S, Heber D, Binderupt L, Uskovic M, Umiel T. .Differentiation of seven human breast cancer cells. In: The proceeding of the ninth workshop on Vitamin D. Walter de Grupter Publishing Co., 1994.
Umiel T, Saltz-Tal E. Expression of activation antigens on mitogen stimulated T cells detection by monoclonal antibodies. In: Leukocyte typing II. Eds., E.L. Reinherz, B.F. Haynes, L.M. Nadler and I.D. Bernstein. Springer-Verlag Publisher, New York, 1985, pp. 442-451.
Umiel T, Schlossman SF, Reinherz EL. A functionally unique IL-2 responsive human cortical subpopulation expresses mature T cell antigens. In: Current concepts in Human Immunology and Cancer Immunodulation. Eds., B. Serrou and C. Rosenfeld. Elsevier Press, Sci Publisher, New York, 1982, pp. 31-48.
Carnaud C, Umiel T, Gestinel L. Frequency and restriction of cytotoxic T lymphocyte precursors in neonatally thymectomized mice. In: Advances in Experimental Medicine and Biology. Eds., P. Nienwenhuis, A.A. van den Broek, M.G. Hanna-J. Plenum Press Publishing Co., New York, 1982, pp. 149-295.
Umiel T, Rabinovich H, Globerson A. Suppression of a response to modifier self cells by mouse fetal liver cells. In: Aspects of Development and Comparative Immunology-I. Ed., J.B. Solomon. Pergamon Press, New York, 1981, pp. 423-429.
Trainin N, Umiel T, Klein B, Kleir I. The role THF, a thymic hormone in the physiology of the thymus. In: Polypeptide Hormones. Eds., R.F. Beer, Jr. and E.G. Basset. Raven Press, New York, 1980, pp. 467-488.
Trainin N, Umiel T, Yakir Y. Biological effects of THF on thymus cell subpopulations in mice. In: Thymus, Thymic Hormones and T-lymphocytes. Eds., F. Aiuti and H. Wigzel. Academic Press, London, 1980, pp. 201-211.
Zaizov R, Vogel R, Cohen IJ, Dvir A, Shohat B, Umiel T, Pecht M, Trainin N. The immunomodulatory effect of THF in children with acute mylogenous leukemia. In: International Symposium on New Trends in Human Immunology and Cancer Immunotherapy. Eds., B. Serrou and C. Rosenfeld. Doin Editeur, Publisher, 1980, pp. 807-813.
Globerson A, Rabinovich H, Umiel T. Ontogeny of suppressor cells in relation to onset of immune reactivity. In: Aspects of Developmental and Comparative Immunology-I. Ed., D.B. Solomon. Pergamon Press, New York, 1980, pp. 415-521.
Globerson A, Rabinovich H, Umiel T, Reisner Y, Sharon N. Characterization of reactive and suppressive cells in mouse embryonic liver by peanut agglutinin (PNA). In: Function and Structure of the Immune System. Eds., W. Muller-Rucholz and H.K. Muller. Plenum Publishing Co., New York, 1979, pp. 345-359.
Linker-Israeli M, Umiel T, Itzchaki M, Trainin N, Sharon N. Separation of tumor-enhancing murine thymocytes by agglutination with a peanut lectin (PNA). In: Regulatory Mechanisms in Lymphocytes Activation. Academic Press, New York, 1977, pp. 515-517.
Globerson A, Rabinovich H, Umiel T. Ontogeny of suppressor cells. In: Developmental Immunology. Eds., T.B. Solomon and J.K. Horon. Elseivier/ North Holland and Biomedical Press, Amsterdam, 1977, pp. 331-337.
Umiel T. Development of specific suppressor cells of embryonic of neonatal liver origin and their possible role in immunological tolerance. In: Developmental Immunology. Eds., J.B. Solomon and J.D. Horton. Elsevier/North Holland Biomedical Press, Amsterdam, 1977, pp. 232-330.
Umiel T, Altman A, Trainin N. Augmentation of cell mediated lysis (CML) by THF. In: Immune Reactivity of Lymphocytes. Eds., M. Feldman and A. Globerson. Plenum Press Publishing Co., New York, 1976, pp. 639-643.
Umiel T. Immunosuppression by fetal liver as a model for tolerance to self. In: Immune Reactivity of Lymphocytes. Eds., M. Feldman and A. Globerson. Plenum Press Publishing co., New York, 1976, pp. 565-569.
Trainin N, Small M, Zipori D, Umiel T, Kook AI, Rotter V. characteristics of THF, a thymic hormone. In: Biological Activity of Thymic Hormones. Ed., D.W. van Bekkum. Kookyker Scientific Publications, Rotterdam, The Netherlands, 1975, pp. 117-158.
Moss TJ, Cooper B, Lazarus HM, Meagher R, Pecora AL, Herzig RM, Umiel T, Copelan E, Akard L, Jansen J, Kennedy MJ. Immunocytologic analysis of bone marrow taken from patients with stage IV breast cancer undergoing autologous transplant therapy. In: Dicke K, Keating A, eds. Autologous Marrow Transplantation: Proceeding the Eighth International Symposium. Houston. 467-472, 1997.
Auerbach R, Globerson A, Umiel T. The ontogeny of cellular immune reactivity in the mouse. In: Ontogeny and Phylogeny of the RES. N. Cohen and M. Siegel, Eds., Plenum Press Publishing Co., New York, Pp. 687-711, 1982.
Trainin N, Kook A, Umiel T, Albala M. The nature and mechanism of stimulation of immune responsiveness by thymus extracts. Ann NY Acad Sci 249:349-361, 1975.
Globerson A, Umiel T, Friedman D. Activation of immune competence by thymus factors. Ann NY Acad Sci 249:248-257, 1975.
Umiel T, Auerbach R. Studies on the development of immunity: The graft-versus-host reaction. Pathobiol Ann 3:27-45, 1973.
A list of more than 100 oral presentations at scientific meetings is available upon request.